GlassScriptPhysician profile
Neda Mehr
NPI 1841432861
$12,881.41
in general payments reported to CMS, 2019-2025
21 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $987 · 2021: $1,537 · 2022: $7,163 · 2023: $1,366 · 2024: $595 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873 · Travel and Lodging: $2.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.02 |
| Travel and Lodging | $2.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $5,692.97 | 2021-2025 | Clear+Brilliant |
| Merz North America, INC. | $3,798.66 | 2019-2023 | Xeomin |
| Allergan, INC. | $818.73 | 2019-2022 | |
| Biofrontera INC. | $546.13 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $365.72 | 2019-2025 | |
| Abbvie INC. | $298.71 | 2023-2025 | |
| Lilly USA, LLC | $283.81 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Genzyme Corporation | $262.35 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $259.17 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $105.02 | 2023-2025 | |
| Incyte Corporation | $100.68 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $80.85 | 2020-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $50.99 | 2022-2025 | Dupixent |
| Vyne Pharmaceuticals INC. | $37.47 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.65 | 2022-2025 | Siliq, Jublia, Cabtreo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $35.34 | 2025 | Bimzelx |
| Leo Pharma INC. | $29.07 | 2025 | Adbry |
| Organon LLC | $21.39 | 2025 | Vtama |
| Epi Health, LLC | $21.38 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.89 | 2024 | |
| Strata Skin Sciences, INC. | $15.43 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neda Mehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.